701 LEE ROAD, WAYNE, PA
Aclaris Therapeutics Enters Amended ATM Agreement with Leerink and Cantor
Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics Elects Two Directors at 2026 Annual Meeting
Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Investor Presentation
Annual Report to Security Holders
Aclaris Therapeutics Raises $20 Million Through Common Stock Sale
Aclaris Therapeutics Sells 12.7 Million Shares for $39.8 Million
Q2
Q1
FY 2024
Q3
FY 2023
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence